Menu Search
Equities

ValiRx PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
EAJF:FRA

ValiRx PLC

Actions
  • Price (EUR)0.002
  • Today's Change0.002 / 300.00%
  • Shares traded120.00k
  • 1 Year change-33.33%
  • Beta-1.0813
Data delayed at least 15 minutes, as of Feb 17 2026 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.

  • Revenue in GBP (TTM)49.78k
  • Net income in GBP-1.78m
  • Incorporated2000
  • Employees14.00
  • Location
    ValiRx PLCMediCity Nottingham, D6 Thane RoadNOTTINGHAM NG90 6BHUnited KingdomGBR
  • Phone+44 115 784 0025
  • Fax+44 203 008 4415
  • Websitehttps://www.valirx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.